Trial
NCT03673735
Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
—
Condition
Squamous Cell Head and Neck Carcinoma
Intervention
Durvalumab
Why stopped
Company withdrew interest
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-05-10